# FORT-2 (NCT03473756)

> Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03473756
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Bayer
- Conditions: Urothelial Carcinoma
- Interventions: Rogaratinib (BAY1163877); Atezolizumab
- Enrollment: 37
- Primary outcome: Number of Participants With Dose-limiting Toxicities(DLTs)
- Primary outcome: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
- Primary outcome: Number of Participants With Drug-related TEAEs
- Primary outcome: Number of Participants With Treatment-emergent Serious Adverse Events(TESAEs)

## Commentary we found

- X threads: 2
- YouTube: 1
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=fort-2-nct03473756